NASDAQ:SGMO

Sangamo Therapeutics (SGMO) Stock Price, News & Analysis

Sangamo Therapeutics logo
$0.07 0.00 (0.00%)
As of 11/6/2026

About Sangamo Therapeutics Stock (NASDAQ:SGMO)

Advanced

Key Stats

Today's Range
$0.07
▼
$0.07
50-Day Range
$0.07
▼
$0.07
52-Week Range
$0.06
▼
$0.77
Volume
N/A
Average Volume
8.10 million shs
Market Capitalization
$30.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Reduce

Company Overview

Sangamo Therapeutics is a biotechnology company developing genomic medicines for serious diseases. Its research focuses on modifying or regulating genes and using engineered cells to produce potential treatments.

The company’s technology platform includes zinc finger proteins, including zinc finger nucleases (ZFNs), which are designed to target specific genetic sequences. Sangamo applies its technologies across gene therapy, cell therapy and gene regulation programs, with research spanning areas such as rare diseases and neurological disorders.

Founded in 1995 and formerly known as Sangamo BioSciences, the company is headquartered in Brisbane, California. It also works with pharmaceutical and biotechnology partners to develop and advance potential therapies.

AI Generated. May Contain Errors.

Receive SGMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SGMO Stock News Headlines

The warning signs most investors see too late
Dr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008.tc pixel
Sangamo Therapeutics Inc SGMO
See More Headlines

SGMO Stock Analysis - Frequently Asked Questions

Sangamo Therapeutics' stock was trading at $0.42 at the start of the year. Since then, SGMO shares have decreased by 82.4% and is now trading at $0.0740.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) issued its quarterly earnings data on Thursday, November, 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by $0.08. The biopharmaceutical company had revenue of $581 thousand for the quarter, compared to the consensus estimate of $34.40 million. Sangamo Therapeutics had a negative net margin of 310.81% and a negative trailing twelve-month return on equity of 2,662.06%.
Read the conference call transcript
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sangamo Therapeutics investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Editas Medicine (EDIT), Micron Technology (MU), Bristol Myers Squibb (BMY), Alibaba Group (BABA) and Advanced Micro Devices (AMD).

Company Calendar

Today
11/22/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SGMO
CIK
1001233
Employees
480
Year Founded
1995

Price Target and Rating

High Price Target
$10.00
Low Price Target
$10.00
Potential Upside/Downside
+13,413.5%
Consensus Rating
Reduce
Rating Score (0-4)
1.67
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.38)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$122.93 million
Net Margins
-310.81%
Pretax Margin
-312.25%
Return on Equity
-2,662.06%
Return on Assets
-132.12%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.84
Quick Ratio
0.84

Sales & Book Value

Annual Sales
$39.55 million
Price / Sales
0.78
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.04) per share
Price / Book
-1.85

Miscellaneous

Outstanding Shares
414,289,000
Free Float
397,291,000
Market Cap
$30.66 million
Optionable
Optionable
Beta
1.30

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:SGMO) was last updated on 11/6/2026 by MarketBeat.com Staff.
From Our Partners